论文部分内容阅读
目的探讨卵巢癌经导管动脉内热化疗的疗效。方法卵巢癌36例,均为失去手术机会或术后复发患者。随机分为治疗组(n=20)和对照组(n=16),治疗组经导管动脉内灌注加热至62℃化疗药液,对照组经导管灌注常温25℃的化疗药液。对比分析2组近期疗效、CA125动态变化,以及介入治疗后的毒副反应。结果治疗后,2组CA125均下降(Ρ<0.05),但治疗组下降更明显(Ρ<0.05)。治疗组有效率(70%)优于对照组(50%),但无统计学差异(Ρ>0.05)。白细胞Ⅰ～Ⅱ度下降等是动脉内化疗的主要不良反应,治疗组发生率20%(4/20),对照组31.3%(5/16),无统计学差异(Ρ>0.05)。结论经导管动脉内热化疗可进一步提高卵巢癌疗效,毒副反应轻。
Objective To investigate the efficacy of transcatheter arterial thermochemotherapy in ovarian cancer. Methods 36 cases of ovarian cancer, all patients lost the chance of surgery or recurrence. The patients in the treatment group were randomly divided into treatment group (n = 20) and control group (n = 16). The patients in the treatment group were treated by intraductal perfusion with 62 ℃ chemotherapy solution. The control group was infused with chemotherapy solution at 25 ℃. Comparative analysis of two groups of recent efficacy, CA125 dynamic changes, as well as the toxic side effects after interventional therapy. Results After treatment, CA125 in both groups decreased (P <0.05), but the treatment group decreased more significantly (P <0.05). The treatment group was more effective (70%) than the control group (50%), but no statistical difference (P> 0.05). The decrease of Ⅰ ~ Ⅱ degree of white blood cells was the main adverse reaction of intra-arterial chemotherapy. The incidence of treatment group was 20% (4/20) and that of control group was 31.3% (5/16). There was no significant difference (P> 0.05). Conclusion Transcatheter arterial thermochemotherapy can further improve the efficacy of ovarian cancer with less toxic side effects.